Egret Therapeutics Inc.
Redefining Recovery After Devastating Injuries
https://wefunder.com/egret.therapeutics
Total raised on Wefunder: 87000
Total investors: 4
Quick facts
- The same immune response drives a second wave of damage after CNS, cardiac and orthopedic injury.
- Prior programs tried to block this immune response and failed - blockade also suppresses repair.
- We found a switch that reprograms these immune cells from destructive to protective.
- EGT-101 is our first-in-class therapy to flip this switch - Phase 1 complete, clean safety profile.
- Phase 1b proof-of-principle trial tracks ICU signals: less swelling, fewer surgeries.
- Co-founded by Stanford's Chair of Neurosurgery and a Johns Hopkins Neurosurgeon.
- $7.5M funds Phase 1b readout - enables Phase 2, pipeline expansion, and licensing and M&A talks.
- Beachhead market is a ~$1B peak sales opportunity; the underlying biology unlocks broader platform.